Main > > >MULTIPLE MYELOMA. *

---

Minimum Residual Disease (MRD). Diag.
& Monitoring Assay.
USA Approval Date: 2018. 09.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.15.




Prognostics. New Diag>High/Low Risk>
>Activity of 92 Genes
EU Approval Date: 2015. 11.25.
(*) Company; Patent APP., TradeMark &
Web-Site Available on Request.
UpDate: 2018. 11.20.




Skeletal-Related Events (SRE) Prevention
DenosuMAb Inj.
CN Approval Date: 2020. 11.19.
USA Approval Date: 2018. 01.05.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.11.




TREAT.: Autologous Stem Cell Transplan-
tion (ASCT).
Melphalan.HCl for Inj.
Use as High-Dose Conditioning Treatment Prior to ASCT.
CN Approval Date : 2018. 12.03.
USA Approval Date: 2016. 03.15.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 12.04.




TREAT.: Autologous Stem Cell Transplan-
tation (ASCT).
Plerixafor Inj.+Granulocyte-Colony Stimulating Factor (G-CSF) Indicated
to Mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation.
USA Approval Date: 2008. 12.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.21.




TREAT.: Bortezomib for Inj. Brand.
(*) Company : Takeda Oncology.
Patent : Expired.
TradeMark: Velcade.
Web-Site : www.velcade.com/
UpDate: 2018. 11.20.




TREAT.: Bortezomib for Inj. Generic.
USA Launch Date: 2018. 01.12.
(*) Company: Fresenius Kabi.
UpDate: 2018. 11.20.




TREAT.: Carfilzomib for Inj.
[Recurrent/Refractory (R/R)].
Proteasome Inhibition
USA Approval Date: 2012. 07.20.>
>Alone & Received >1 Previous Treat.
USA Approval Date: 2020. 08.20.+>
+DaratumuMAb+Dexamethasone
>Received 1-3 Previous Treat.
USA Approval Date: 2015. 07.24.+>
+Dexamethasone or
+Lenalidomide+Dexamethasone
>Received 1-3 Previous Treat.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 09.15.




TREAT.: DaratumuMAb. Combination Therapy
[Newly Diagnosed who Can NOT Receive
Autologous Stem Cell Transplant (ASCT)]
+Bortezomib+Melphalan+Prednisone.
USA Approval Date: 2018. 05.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.29.




TREAT.: DaratumuNAb. Combination Therapy
[Newly Diagnosed who Can NOT Receive
Autologous Stem Cell Transplant (ASCT)]
+Lenalidomide+Dexamethasone.
USA Approval Date: 2019. 06.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.29.




TREAT.: DaratumuMAb. Combination Therapy
[Newly Diagnosed who Can YES Receive
Autologous Stem Cell Transplant (ASCT)]
+Bortezomib+Thalidomide+Dexamethasone.
USA Approval Date: 2019. 09.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.29.




TREAT.: DaratumuMAb. Combination Therapy
[Recurrent/Refractory (R/R)].
+Lenalidomide or Bortezomib+Dexametha-
sone.
>1 Prior Line of Therapy.
USA Approval Date: 2016. 11.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.29.




TREAT.: DaratumuMAb. Combination Therapy
[Recurrent/Refractory (R/R)].
+Pomalidomide+Dexamethasone
>2 Prior Lines Including Lenalidomide
& a Proteasome Inhibitor (PI)
USA Approval Date: 2017. 06.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2019. 12.24.




TREAT.: DaratumuMAb. MonoTherapy.
[Recurrent/Refractory (R/R)].
>Received>3 Prior .. Including>
>a Proteasome Inhibitor & an Immunomo-
dulatory Agent
Mechanism: CD38-Directed MAb.
EU Approval Date : 2016. 05.23.
JP Approval Date : 2017. 09.27.
USA Approval Date: 2015. 11.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.29.




TREAT.: DoxoRubicin Liposome+Bortezomib.
Brand.
[Recurrent/Refractory (R/R)]
Approved
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.20.




TREAT.: DoxoRubicin Liposome+Bortezomib.
Generic.
[Recurrent/Refractory (R/R)]
USA Approval Date: 2017. 05.17.
(*) Company: Dr. Reddy s Laboratories.
UpDate: 2018. 11.20.




TREAT.: ElotuzuMAb for Inj. for IV Use.
(Recurrent/Refractory (R/R)].
EU Approval Date: 2016.05.11.+>
+Lenalidomide+Dexamethasone
>Received 1-3 Prior Therapies.
USA Approval Date: 2015.11.30.+>
+Lenalidomide+Dexamethasone
>Received 1-3 Prior Therapies.
EU Approval Date: 2019.08.27.+>
+Poma;odomide+Dexamethasone
>Received >2 Prior Therapies (Lenalido-
mide & Proteasome Inhibitor)
USA Approval Date: 2018.11.06.+>
+Pomalidomide+Dexamethasone
>Received >2 Prior Therapies (Lenalido-
mide & Proteasome Inhibitor)
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2019. 11.18.




TREAT.: Idecabtagene Vicleucel One-Time Infusion>
[Recurrent/Refractory (R/R)].
>4 Lines of Therapy Including an
immunomodulatory agent, a proteasome
inhibitor, and an anti-CD38 MAb.
CAR T Cell Therapy.
USA Approval Date: 2021. 03.26.
(*) Company; Patents; & Product Name
Available on Request.
UpDate: 2021. 03.29.




TREAT.: IsatuxiMAb+>
[Recurrent/Refractory (R/R)].
Mechanism: Binds CD38 Receptor.
+Pomalidomide+Dexamethasone
>2 Prior Therapies Lenalidomide &
Proteasome Inhibitor
Note Related to Patent:
Claim 1: Anti-CD38 Antibody (Isatuxi-
MAb)+Lenalidomide
CA Approval Date: 2020. 07.08
USA Approval Date: 2020. 03.02.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.27.




TREAT.: Ixazomib Capsules+Lenalidomide+
Dexamethasone.
Mechanism: Proteasome Inhibitor.
CA Approval Date : 2016. 08.08.
USA Approval Date: 2015. 11.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.20.




TREAT.: Lenalidomide Capsules.
USA Approval Date: 2006.00.00>
>+dexamethasone in patients with
multiple myeloma who received at least
one prior therapy.
USA Approval Date: 2015.00.00>
>+dexamethasone for the treatment of
patients with multiple myeloma, to
include newly diagnosed multiple
myeloma patients who are not eligible
for autologous stem cell transplant.
USA Approval Date: 2017.02.22>
>maintenance therapy for patients with
multiple myeloma following autologous
stem cell transplant.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.08.




TREAT.: Melphalan Flufenamide+Dexametha- sone>>
(R/R)
>4 prior lines of therapy
>refractory to at least one proteasome
inhibitor, one immunomodulatory agent,
and one CD38-directed MAb.
USA Approval Date: 2021. 02.26.
USA Launch Date: 2021. 03.15.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2021. 03.16.




TREAT.: Panobinostat Capsules+Bortezomib
+DExamethasone
[Recurrent/Refractory (R/R)]
>Received > 2 Prior Regimens including
Bortezomib & ImmunoModulatory Agent
EU CE Mark Date : 2015. 08.28.
USA Approval Date: 2015. 02.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.27.




TREAT.: Plitidepsin+
[Recurrent/Refractory (R/R)].
+Dexamethasone.
AU Approval Date: 2018. 12.11.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 12.12.




TREAT.: Pomalidomide Capsules.
[Recurrent/Refractory (R/R)].
+Dexamethasone
>Received>2 Prior Therapies.>
Lenalidomide+Proteasome Inhibitor
EU Approval Date : 2013. 08.09.
USA Approval Date: 2013. 02.08.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2018. 11.09.




TREAT.: Selinexor Tab.+Dexamethasone
[Recurrent/Refractory (R/R)]
>Received > 4 Prior Therapies.
Nuclear Export Inhibitor
Refractory to >
>Anti-CD38 MAb
>2 Immunomodulatory Agents
>2 Proteasome Inhibitors (PI)
EU Approval Date: 2021. 03.29.
IL Approval Date: 2021. 02.04.
USA Approval Date: 2019. 07.03.
USA Launch Date : 2019. 10.08.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2021. 03.30.




TREAT.: Thalidomide Cap.+Dexamethasone
(Newly Diagnosed)
USA Approval Date: 2006. 05.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.21.




TREAT.: Zoledronic Acid Inj. IV.
USA Initial Approval Year: 2001.
(*) Company : Novartis.
Patent : Expired
TradeMark: Zometa.
UpDate: 2018. 11.20.


>MULTIPLE MYELOMA. *'s products
This section has no products